Abstract
This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Current Drug Targets
Title:Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
Volume: 14 Issue: 7
Author(s): Bernard Le Foll, Patricia Di Ciano, Leigh V. Panlilio, Steven R. Goldberg and Roberto Ciccocioppo
Affiliation:
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Abstract: This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Export Options
About this article
Cite this article as:
Foll Bernard Le, Ciano Patricia Di, Panlilio Leigh V., Goldberg Steven R. and Ciccocioppo Roberto, Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070006
DOI https://dx.doi.org/10.2174/1389450111314070006 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ
Current Vascular Pharmacology Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Comparison of Midwifery Consultation and Fluoxetine on IVF Outcomes in Depressed Infertile Women: A Clinical Trial Research Study
Current Women`s Health Reviews Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry Novel Neuropeptides as Ligands of Orphan G Protein-Coupled Receptors
Current Pharmaceutical Design Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Towards an Integrated Clinical Psychobiology of Alcoholism
Current Psychiatry Reviews Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression
CNS & Neurological Disorders - Drug Targets How Satiety Factors Reach CNS Appetite Centers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data
Current Neuropharmacology Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery